Regulation of translation dynamic and neoplastic conversion by tRNA and their pieces

Renaud Geslain* and Gilbert Eriani†*

1Laboratory of tRNA Biology; Department of Biology; College of Charleston; Charleston, SC USA; 2Architecture et Réactivité de l’ARN, Université de Strasbourg; CNRS; Institut de Biologie Moleculaire et Cellulaire; Strasbourg CEDEX, France

Keywords: transfer RNA, translation, misacylation, tRNA fragments, cancer, oxidative stress, gene regulation

Abbreviations: tRNA, transfer RNA molecule; RNase, ribonuclease; ROS, reactive oxygen species; MetRS, methionyl-tRNA synthetases; tRFs, tRNA-derived RNA fragments; PBS, primer binding site

Introduction

In eukaryotes, tRNA genes are massively transcribed by RNA polymerase III. Millions of tRNAs molecules are synthesized per generation, which represent, at any time, at least 30% of all RNA in a cell.1 tRNA transcription comes at an obvious and tremendous energetic cost and therefore needs to be tightly regulated in response to nutrient availability and cellular fitness.

A portion of the RNA polymerase III promoter resides within each eukaryotic tRNA gene (Fig. 1). This internal promoter encompasses two distinct regions corresponding to nucleotides 8–19 (box A) and 52–62 (box B) of tRNA.2 tRNA biogenesis involves the synthesis of an initial transcript containing a 5′ leader sequence, which is subsequently removed by the endonuclease RNase P.3 Maturation of the 3′ end requires trimming the 3′ trailer and subsequent addition of CCA after the discriminator base N73 (Fig. 2). Only a small fraction of tRNA genes contain introns that are invariably found between nucleotides 37 and 38.3 Splicing of tRNAs is essential and involves only a limited number of proteins as opposed to spliceosome-mediated mRNA splicing. Prior to their export from the nucleus to the cytoplasm, freshly processed tRNAs are extensively modified. On average 14 modifications are added post-transcriptionally in eukaryotic tRNAs.6 The structure and the position of these modifications modulate tRNA activity to different extents. Modifications in or around the anticodon loop tune translation rate and impact cellular growth.7 Modifications in the main body typically affect tRNA folding and stability.8,9

Basal tRNA Expression in Human

Organization of tRNA genes in the human genome
tRNAs were long considered as archetypical house-keeping molecules. They were thought to serve an exclusive role in protein translation and supposedly lacked regulatory functions. Prior to the human genome-sequencing project, human tRNAs were expected to be no more diverse than those in unicellular organisms.

The human genome encodes around 500 tRNA genes, which represent five times the tRNA gene population in the bacteria E. coli. These genes are found throughout the genome and are present on all but the Y chromosome.10 The mitochondrial DNA encodes an additional 22 tRNA genes. The corresponding tRNAs are grouped into 49 isoacceptor families and decode 21 amino acids. Interestingly, the largest cluster of tRNA genes resides in the gene cluster of the major histocompatibility complex also known as the leukocyte antigen complex. This colocalization suggests a potential coordination between canonical protein translation and immune system functions.11

Another remarkable and unforeseen feature of tRNA that was revealed by genome sequencing is the proliferation of tRNA isodecoder genes. Isodecoders share identical anticodon sequence but display differences elsewhere in the tRNA body. The number and percentage of such tRNA genes follows remarkably the phylogenetic arrangement of living organisms. This fraction is < 10% in the budding yeast, 12–18% in fruit flies and worms and increases to 35–46% in chickens, dogs, rats, and mice.10 In humans > 50%
of tRNA genes are isodecoders (Fig. 3). Isodecoders have identical decoding capacity and therefore appear redundant at first glance. In reality, tRNA isodecoders display significant functional variations. An increasing body of evidence suggests that some isodecoders, particularly those with low affinity for the translation machinery, perform functions beyond protein synthesis and act as potent cell regulators.12,13

**Differential tRNA expression in healthy human tissues**

Global tRNA expression is theoretically adjustable. tRNAs are transcribed by RNA polymerase III and its associated transcription factors, TFIIB and TFIIC. On one hand, intracellular abundance of these two essential factors is subjected to regulation as suggested by results from mRNA expression arrays.14 Alternatively, TFIIB and TFIIC activities can be modulated at the post-translational level.15

Regulation of the expression of individual isodecoders is also possible. Only a few nucleotides in the internal tRNA gene promoter are highly conserved because of their involvement in the tRNA tertiary structure. Seven nucleotides within box A and 6 nucleotides within box B are variable. These sequence differences

---

**Figure 1.** Cloverleaf folding of tRNA (tRNA). The standard cloverleaf structure (2D) and conventional numbering is shown. Conserved nucleotides are indicated (T and Ψ are modified residues: ribothymidine and pseudouridine; R are for purines and Y for pyrimidines). Watson-Crick base pairings and G-U pairs are shown; thin black lines indicate long-distance base pairings involved in tertiary folding (3D, upper right panel).
could modulate the promoter strength by increasing or lowering the binding affinity for the aforementioned transcription factors.

Comparative tRNA expression in brain, liver, vulva, testis, ovary, thymus, lymph node, and spleen tissue show that tRNA concentrations vary by as much as 10-fold among these eight organs. The three immune tissues contain increased levels of tRNAs charged with hydrophobic amino acids and decreased levels of tRNAs for the charged group compared with brain tissue. In contrast, the two reproductive tissues contain decreased levels of tRNAs for the hydrophobic group and increased levels of tRNAs for the small side chain group. It appears that cellular tRNA concentrations naturally adjust to codon usage in order to maintain translation speed and limit ribosomal drop-off. Ribosomal proteins constitute by far the largest fraction of the proteome and therefore predominantly influence tRNA distribution. Tissue-specific genes are sometimes expressed at a rate comparable to ribosomal components. Because these tissue-specific proteins are synthesized at such a high level they are directly responsible for the partial reprogramming of tRNA expression.

**tRNAs are Overabundant in Cancer Cells**

In multiple myeloma

In multiple myeloma (MM), malignant plasma cells overexpress cytosolic tRNAs. Levels of tRNAs derived from chromosomal-encoded genes are elevated by 2- to 4-fold, whereas the levels of tRNAs derived from mitochondrial-encoded genes remain unchanged (Fig. 4). Myeloma cells are also characterized by the production and secretion of large amounts of monoclonal antibodies.

In breast cancer

tRNAs are invariably overexpressed in breast cancer cells and the corresponding expression patterns are remarkably conserved across the major subtypes of breast cancer. Cellular concentrations of nuclear- and mitochondrial-encoded tRNAs increase by up to 5-fold in breast cancer cell lines vs. non-cancer derived cell lines. Interestingly, this difference is even more pronounced when malignant cells are compared with regular primary cells. Indeed, breast tumor cells express 10 times more nuclear- and mitochondrial-encoded tRNAs than the corresponding healthy breast tissue.

**Functional consequence**

Deregulation of RNA polymerase III and abnormal levels of pol III transcripts is common in a wide range of transformed cells. Cancer cells often overexpress TFIII factors, which subsequently lead to overexpression of tRNA8,9. In addition, polyploidy or genomic instability together with changes in chromatin structure drastically impact the expression of hundreds of genes in cancer relative to healthy cells. Chaotic and unpredictable tRNA expression in pathological cells would be an expected consequence. Surprisingly, transformed and cancerous cells preserve balanced tRNA pools that resemble the pools of healthy cells although they express considerably more tRNA molecules than regular cells. In cancer cells, tRNA expression is regulated globally and simultaneously on the entire collection of tRNA genes.

**Central Role for tRNAMet and MetRS**

Artificial overexpression of initiator tRNAMet reprograms overall tRNA expression

Global regulation of tRNA expression in cancer cells enables simultaneous and coordinated transcription of all tRNAs. By definition, the same mechanism inhibits or keeps in check the overexpression of single tRNA species. Because tRNAs were long considered non-regulatory housekeeping genes, there are no well-established efficient methods for redistributing tRNA levels in mammalian cells. In addition, since tRNAs are so abundant, a mere 2-fold overexpression requires the biosynthesis and maturation of an additional 1,000,000 tRNAs per cell. Artificial
tRNA overexpression in cancer cells requires the generation of stable cell lines and only modest but nonetheless significant increase (1.4- to 2.2-fold) can be achieved. Interestingly, even low expression of additional initiator tRNA\textsubscript{Met} in non-tumorigenic cells increases cell metabolism and proliferation. A rush of initiator tRNA in the translation machinery may have two consequences. First, it may boost global mRNA translation and stimulate overall protein synthesis. Second, it may favor translation of mRNA encoding cell-cycle or anti-apoptotic proteins such as Myc or Cyclin D1 and drive the cell toward a more defined and pronounced pro-cancer state. Overexpression of initiator tRNA\textsuperscript{Met} also globally increases tRNA levels, confirming the necessity to maintain a balanced pool of tRNAs in fast dividing cells. Between the two options of actively degrading excess of initiator tRNA and raising the rest of the tRNA pool up to the level of the initiator tRNA, cells choose the latter against all energetic considerations.

**Misacylation of tRNA by methionyl-tRNA synthetase has been observed in bacteria, yeast, and mammals**

tRNA-microarray analyses have demonstrated that methionyl-tRNA synthetases (MetRS) from *Escherichia coli*, *Saccharomyces cerevisiae*, and humans misacylate non-cognate tRNAs with methionine. These misacylated species are used in translation and lead to the synthesis of mutant proteins with potential new features or properties.

*E. coli* MetRS mismethionylates only two *E. coli* tRNA species in vitro, one tRNA\textsuperscript{Thr} and one tRNA\textsuperscript{Arg}. Strong and very specific interactions between residues of the enzyme and the anticodon stimulate or alternatively prevent the transfer of methionine onto the tRNA. Therefore, only a very limited set of non-methionine tRNAs display identity elements for mismethionylation. On the contrary, *S. cerevisiae* MetRS mismethionylates a wide range of non-methionine tRNAs. The magnitude of mismethionylation depends directly on growth conditions. At stationary phase, mismethionylation culminates and one in every ten methionine is transferred onto non-cognate tRNAs. The yeast MetRS is part of a unique three-protein complex that includes a general tRNA-binding protein, Arc1p and the glutamyl-tRNA synthetase. This complex equips yeast MetRS with strong and non-specific tRNA binding abilities explaining the extensive level of misacylated tRNAs in that species. In unstressed mammalian cells, approximately 1% of the methionylated tRNAs are non-cognate and

---

**Figure 3.** Number of tRNA genes and isodecoder genes across the phylogenetic spectrum. Eukaryotic genomes contain between 200 and 450 tRNA genes encoding 41 to 55 tRNA isoacceptors (tRNAs with different anticodons). The number of tRNA genes having the same anticodon but different sequences elsewhere in the tRNA body (tRNA isodecoders) varies significantly and is increasing across the phylogenetic spectrum. Sequence variations in tRNA isodecoders are concentrated in the internal promoter regions for RNA polymerase III.
Methionine misacylation protects cells against oxidative stress

Many cellular stressors trigger the release of reactive oxygen species (ROS). ROS damage cellular components in general and oxidize the highly reactive sulfur in methionine residues in particular. Proteins have evolved to minimize the impact of ROS by hiding functional residues such as histidine, tryptophan, cysteine or methionine behind protein motifs displaying decoy or non-essential methionine.25 Mismethionylation and subsequent misincorporation of methionine residues in neo-synthesized proteins enhances the protective function of genetically encoded decoy methionine residues. This complementary pathway is induced rapidly and allows immediate extra-genetic incorporation of methionine in response to increased ROS levels. An obvious side effect of this mechanism is the apparent undesirable synthesis of catalytically inactive or misfolded proteins. These aberrant proteins constitute only a minor fraction of the mismethionylation-derived protein pools, as other proteins would contain extra methionine in positions with minimal disturbance to catalytic activity or structure. Rapid containment of ROS comes at a cost and these proteins are the result of a cellular compromise.

Figure 4. Differential tRNA expression in seven different human tissues measured by tRNA microarrays. Tumor cells generally express higher levels of nuclear encoded tRNA than every tissue examined.
of reporter genes in vivo and in vitro although they intrinsically have little to no ability to base pair with their primary targets. An unexpected and recent report has shown that a 5’rRF derived from tRNAVal downregulates protein synthesis in the archaeon Haloferax volcanii by interfering with the small ribosomal subunit. 3′CCA tRFs are emerging cellular regulators with tremendous biomedical potential. Retroviruses like the Human immunodeficiency virus (HIV-1) highjack cellular tRNA Lys, tRNAPro, or tRNATrp in order to replicate their genome. In other words, these tRNAs bind to retroviral primer binding site (PBS) and serve as primers to initiate reverse transcription. Interestingly, 3′CCA tRFs originating from human tRNA Lys maintain their PBS binding ability. It was initially believed that these fragments could be used as antiviral countermeasures by competing with tRNA Lys. A report published in 2009 revealed the true extent of 3′CCA tRFs’ regulatory functions. Viral PBS base pairing with these fragments becomes excellent substrate for Dicer 26 (Fig. 6). The cleavage of PBS gives rise to another short RNA named PBSnc RNA, which inhibits HIV replication most likely through RNAi pathways. A significant fraction of the human genome is made of relics of retroviral sequences. Many identified 3′U tRFs are highly complementary to endogenous retroviral PBS. tRNA fragments constitute a potential reservoir of molecules able to keep the expression of viral sequences in check. 3′U tRFs are derived from the 3′ trailer of tRNA precursors (Fig. 6). These fragments typically display five to six consecutive uridine residues at their 3′ end, which correspond to the canonical RNA polymerase III stop signal. 3′U tRFs are found exclusively in the cytoplasm suggesting instant export from the nucleus to the cytoplasm or alternative pre-tRNA processing by a cytosolic form of RNase Z. 3′U tRFs are essential and potent regulators of cellular proliferation, they are consistently overexpressed in cancer cell lines. RNaseZ, an enzyme essential for their biogenesis, is also known as the prostate cancer susceptibility gene ELAC2. 3′U tRFs bind preferentially the non-splicing AGO3 and 4. The cellular impact of these fragments is therefore RNAi independent and likely to be indirect. First, the saturation of AGO3 and 4 could potentiate the silencing activity of miRNA by favoring their binding to effector AGO1 and 2. Second, AGO3 and 4 are involved in various cellular pathways and their binding to 3′U tRFs could modulate their activity. For example, AGO4 stimulates spermatogenesis and regulates cell cycle. AGO3 participates in Alu RNA guided mRNA decay during stem cell proliferation.

Conclusion

Five decades of intensive research has revealed the function of tRNAs in protein biosynthesis at the atomic, molecular and cellular level. The recent standardization of high throughput approaches opens whole new perspectives by boosting the discovery of new tRNA functions and allowing the scientific community to appreciate the extent of their ramifications. New functions could not have been envisioned due to their intricacy and apparent functional distance to the translation machinery. tRNAs have tremendous potential for cellular regulation as a full-length molecule but also when shattered into pieces. How an ancient housekeeping RNA evolved to become such a potent, versatile, and specific cellular regulator still remains elusive. However some obvious tRNA features have most certainly facilitated or even driven this transition. First and foremost, tRNAs are extremely abundant and consequently highly redundant. A significant number of tRNA molecules can be rechanneled, away from the translation machinery, without perturbing the dynamic of protein synthesis. Second, tRNA sequences are highly malleable. Myriads of compensatory mutations allow the shuffling of nucleotides without affecting functional folding. Finally, this ubiquitous and primordial molecule coevolved with literally every living organism. This early coexistence gave tRNAs the unique opportunity to interact with a wide variety of cellular mechanisms and grow deep ramifications within modern pathways. The cellular network of molecular interactions constitutes in many ways the utmost jigsaw. Tremendous progress has been made toward solving this puzzle and many parts have been
assembled independently of each other. TRNAs could be one of the puzzle pieces needed to kilt these parts together.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
The College of Charleston and Centre National de la Recherche Scientifique (ANR11SVSE8–025–01) sponsor the authors’ current research activities. We thank Jomel Jacinto and Joseph Karam from the College of Charleston for comments on this manuscript.

Figure 6. Model for tRNA fragments biogenesis. tRNA fragments originate from enzymatic digestion of mature and precursor tRNA. tRNA halves, tRFs, and 3’ tails are the products of different pathways.

References
1. Waldron C, Lacroute F. Effect of growth rate on the amounts of ribosomal and transfer ribonucleic acids in yeast. J Bacteriol 1975; 122:855-65; PMID:1097403
2. Galli G, Hofstetter H, Birnstiel ML. Two conserved sequence blocks within eukaryotic tRNA genes are major promoter elements. Nature 1981; 294:626-31; PMID:7312050; http://dx.doi.org/10.1038/294626a0
3. Walker SC, Engelke DR. Ribonuclease P: the evolution of an ancient RNA enzyme. Crit Rev Biochem Mol Biol 2006; 41:77-102; PMID:16595295; http://dx.doi.org/10.1080/10409230600602634
4. Dubrovsky EB, Dubrovskaya VA, Levinger L, Schiffer S, Marchfelder A. Drosophila RNase Z processes mitochondrial and nuclear pre-tRNA 3’ ends in vivo. Nucleic Acids Res 2004; 32:255-62; PMID:14719223; http://dx.doi.org/10.1093/nar/gkh182
5. Marck C, Grosjean H. tRNomics: analysis of tRNA genes from 50 genomes of Eukarya, Archaea, and Bacteria reveals anticodon-sparing strategies and domain-specific features. RNA 2002; 8:1189-232; PMID:12403461; http://dx.doi.org/10.1017/ S1355838202022021
6. Machnicka MA, Milanowska K, Osman Ogrou O, Purra E, Kurkowska M, Olchowiek A, Januszewski W, Knalowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS: a database of RNA modification pathways—2013 update. Nucleic Acids Res 2013; 41:D262-7; PMID:23118484; http://dx.doi.org/10.1093/nar/gkt1007
7. El Yacoubi B, Hatin I, Deutsch C, Kahveci T, Rousset JP, Iwata-Reuyl D, Murzin AG, de Crécy-Lagard V. A role for the universal Kae1/Qri7/YgjD (COG0533) family in tRNA modification. EMBO J 2011; 30:882-93; PMID:21285948; http://dx.doi.org/10.1038/emboj.2010.363
8. Sengupta R, Vainauskas S, Yarian C, Sochacka E, Malkiewicz A, Guenther RH, Koslap KM, Agra PF. Modified constructs of the tRNA TPuC domain to probe substrate conformational requirements of m(1)A(58) and m(5)U(54) tRNA methyltransferases. Nucleic Acids Res 2000; 28:1374-80; PMID:10684932; http://dx.doi.org/10.1093/nar/28.6.1374
9. Helm M, Giegé R, Florentz C. A Watson-Crick base-pair-disrupting methyl group (m1A9) is sufficient for cloverleaf folding of human mitochondrial tRNALys. Biochemistry 1999; 38:13338-46; PMID:10529209; http://dx.doi.org/10.1021/bi99106ig
10. Goodenbour JM, Pan T. Diversity of tRNA genes in eukaryotes. Nucleic Acids Res 2006; 34:6137-46; PMID:17088292; http://dx.doi.org/10.1093/nar/gkl725
11. Dittmar KA, Goodenbour JM, Pan T. Tissue-specific differences in human transfer RNA expression. PLoS Genet 2006; 2:e221; PMID:17194224; http://dx.doi.org/10.1371/journal.pgen.0020221
12. Geslain R, Pan T. Functional analysis of human tRNA isoacceptors. J Mol Biol 2010; 396:821-31; PMID:20026070; http://dx.doi.org/10.1016/j.jmb.2009.12.018
13. Rudinger-Thioron J, Lesure A, Paulus C, Frugier M. Processing of tRNA. Isoacceptor binding and neutralizes a 5′ UTR-embedded Ala element. Proc Natl Acad Sci U S A 2011; 108:E794-802; PMID:21896722; http://dx.doi.org/10.1073/pnas.1010503
14. Su A, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, pnas.1103698108
15. Conesa C, Swanson RN, Schultz P, Oudet P, Sentanac A. On the subunit composition, stoichiometry, and phosphorylation of the yeast translation factor TFIH/tau. J Biol Chem 1993; 268:18047-52; PMID:7688737
16. Mahlab S, Tuller T, Linial M. Conservation of the tRNA anticodon in healthy and cancerous tissues. RNA 2012; 18:640-52; PMID:22357911; http://dx.doi.org/10.1016/j.rna.2012.03.077.151
17. Zhou Y, Goodenour JM, Godley LA, Wickrema A, Pan T. High levels of tRNA abundance and alteration of mRNA charging by borreliobomb in multiple myeloma. Biochem Biophys Res Commun 2009; 355:160-4; PMID:19455555; http://dx.doi.org/10.1016/j.bbrc.2009.05.031
18. Pavon-Eternod M, Gomes S, Geslain R, Dai Q, Rosner MR, Pan T. tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res 2009; 37:2768-80; PMID:19738824; http://dx.doi.org/10.1093/nar/gkp787
19. Winters AG, Sourvinos G, Allison SJ, Tosh K, Scott PH, Spandios DA, White RJ. tRNA polymerase III transcription factor TFIH/tau is overexpressed in ovarian tumors. Proc Natl Acad Sci U S A 2000; 97:12619-24; PMID:11058163; http://dx.doi.org/10.1073/pnas.230224097
20. Marshall L, White RJ. Non-coding RNA production by tRNA polymerase III is implicated in cancer. Nat Rev Cancer 2008; 8:911-4; PMID:18997655; http://dx.doi.org/10.1038/nrc2539
21. Pavon-Eternod M, Gomes S, Rosner MR, Pan T. Overexpression of initiator methionine tRNA leads to nucleotide misprogramming of RNA expression and increased proliferation in human epithelial cells. RNA 2013; 19:461-6; PMID:23431330; http://dx.doi.org/10.1261/rna.037507.112
22. Jones TE, Alexander KW, Pan T. Miscylation of species response and adaptation. Annu Rev Genet 2013; 47:121-37; PMID:23988117; http://dx.doi.org/10.1146/annurev-genet-111212-133522
23. Zhou H, Bojanowski K, Inger DE, Panigraphy D, Pepper MS, Montesano R, Shing Y. New role for tRNA and its fragment purified from human urinary bladder carcinoma conditioned medium: inhibition of endothelial cell growth. J Cell Biochem 1999; 76:109-17; PMID:1050000; http://dx.doi.org/10.1002/(SICI)1097-4644(20000110)100:1<19::AID-JCB13>3.0.CO;2-K
24. Babinet JE, Ruby KG, Wang Y, Barrett DL, Bleloch R. Mouse ES cells express endogenous sRNAs, sRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev 2008; 22:2775-85; PMID:18923076; http://dx.doi.org/10.1101/gad.1705308
25. Calabrese JM, Seila AC, Yeo GW, Sharp PA. RNA sequence analysis defines Dice's role in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2007; 104:18097-102; PMID:17899215; http://dx.doi.org/10.1073/pnas.0701913104
26. Kawai H, Nakamura M, Takahasi Y, Sandellin A, Katayama S, Fukuda S, Daub CO, Kai C, Kawai J, Yauada J, et al. Hidden layers of human small RNAs. BMC Genomics 2008; 9:157; PMID:18402656; http://dx.doi.org/10.1186/1471-2164-9-3-157
27. Lee SR, Collins K. Starvation-induced cleavage of the tRNA anticodon loop in Thermatambrya thermophila. J Biol Chem 2005; 280:42744-9; PMID:16272149; http://dx.doi.org/10.1074/jbc.M510365260
28. Zhang S, Sun L, Kragler F. The phloem-delivered RNA pool contains small noncoding RNAs and interferes with translation. Plant Physiol 2009; 150:378-87; PMID:19621675; http://dx.doi.org/10.1104/pp.108.134767
29. Haisser HJ, Karginov FV, Hannon GJ, Elliot MA. Small RNAs derived from the tRNA anticodon loop in Tetrahymena thermophila. RNA 2009; 15:10494-506; PMID:22941646; http://dx.doi.org/10.1038/nrc2539
30. Buchan JR, Parker R. Eukaryotic stress granules: the convergence of oxidative stress in eukaryotes. RNA 2008; 14:2095-103; PMID:18771924; http://dx.doi.org/10.1261/rna.1323808
31. Ivanov P, Emara MM, Villen J, Gygi SP, Anderson P. Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell 2011; 43:631-23; PMID:21858500; http://dx.doi.org/10.1016/j.molcel.2011.06.022
32. Buchanan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol Cell 2009; 36:932-41; PMID:20064660; http://dx.doi.org/10.1016/j.molcel.2009.11.020
33. Gehweiler J, Zywicky M, Kuzmi A, Polack E. tRNA-derived fragments target the ribosome and function as regulatory non-coding RNA in Haloferax volcanii. Archaea 2012; 2012:260999.
34. Goodchild J, Agrawal S, Civeira MP, Sarin PS, Sun D, Zamecnik PC. Inhibition of human immuno- tolerance virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 1988; 85:5507-11; PMID:304144; http://dx.doi.org/10.1073/pnas.85.15.5507
35. Yeung ML, Benssayer T, Watashi K, Le SY, Houzet L, Beaucage L, Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res 2009; 37:6757-86; PMID:19729508; http://dx.doi.org/10.1093/nar/gkp787
36. Elbaharay RA, Takaku H, Uchiyuni N, Tamiya H, Abe M, Takahashi M, Nishida H, Nashimoto M. Isolation of abundant Dicer-dependent small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. Nucleic Acids Res 2012; 40:6787-99; PMID:22492706; http://dx.doi.org/10.1093/nar/gks507
37. Haussesser D, Huang Y, Lau A, Parameswaran P, Fire AZ, Kay MA. Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA 2010; 16:673-95; PMID:20817388; http://dx.doi.org/10.1261/rna.2008010
38. Hu Q, Feng J, Liu Q, Sun F, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett 2009; 583:437-42; PMID:19140440; http://dx.doi.org/10.1016/j.febslet.2008.12.014
39. Garcia-Silva MA, Frugier M, Tosar JP, Correa- Domínguez A, Rotalle-Alves L, Parado-Talce A, Rosetti C, Pavlocco C, Goldberg S, Caputo A. A population of tRNA-derived small RNAs is actively produced in Trypanosoma cruzi and recruited to specific cytoplasmic granules. Mol Biochem Parasitol 2010; 171:64-75; PMID:19420950; http://dx.doi.org/10.1016/j.molbiopara.2010.02.003